A new product for cancer patients with severe pain that breaks through regular narcotic therapy has been approved by FDA.
Actiq is a form of fentanyl citrate, an opioid narcotic more powerful than morphine. The medicine is in the form of a flavored sugar lozenge that dissolves in the mouth while held by an attached handle.
Many cancer patients experience persistent pain that is treated with oral narcotics. But these patients can experience acute breakthrough pain, with sudden onset that occurs spontaneously or as a result of activity.
Actiq is dissolved slowly in the mouth until the drug is consumed, about 15 minutes. Pain relief may last several hours, starting while the drug is still being consumed.
During clinical trials, side effects included sleepiness, dizziness, nausea, and constipation.
Because Actiq may be fatal to children, as well as adults not already taking opioid narcotics, FDA approved the new drug under special regulations that restrict its distribution. A risk management plan is in place to minimize the opportunity for misuse of the potent narcotic.
Anesta Corporation, Salt Lake City, markets Actiq with partner Abbott Laboratories.
COPYRIGHT 1999 U.S. Government Printing Office
COPYRIGHT 2004 Gale Group